CZ248798A3 - Farmaceutický prostředek - Google Patents
Farmaceutický prostředek Download PDFInfo
- Publication number
- CZ248798A3 CZ248798A3 CZ982487A CZ248798A CZ248798A3 CZ 248798 A3 CZ248798 A3 CZ 248798A3 CZ 982487 A CZ982487 A CZ 982487A CZ 248798 A CZ248798 A CZ 248798A CZ 248798 A3 CZ248798 A3 CZ 248798A3
- Authority
- CZ
- Czechia
- Prior art keywords
- phenyl
- pharmaceutical composition
- loratadine
- composition according
- sodium
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960003088 loratadine Drugs 0.000 claims abstract description 12
- 208000006673 asthma Diseases 0.000 claims abstract description 5
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims abstract 7
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims description 7
- 229960001951 montelukast sodium Drugs 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 2
- SRJDFSRXQHFSBO-UHFFFAOYSA-N acetic acid;methylcyclopropane Chemical compound CC1CC1.CC(O)=O SRJDFSRXQHFSBO-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229960004764 zafirlukast Drugs 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000002617 leukotrienes Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NBQKINXMPLXUET-UHFFFAOYSA-N Pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 NBQKINXMPLXUET-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- -1 elixirs Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OQFHCJMOQCAFIL-UHFFFAOYSA-N acetic acid;cyclopropane Chemical compound C1CC1.CC(O)=O OQFHCJMOQCAFIL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940106779 montelukast 10 mg Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Farmaceutický prostředek
Oblast techniky
Vynález se týká farmaceutického prostředku s antiasthmatickým, antialergickým a protizánětlivým účinkem. Dosavadní stav techniky
Loratadin je antihistaminová látka s antagonistickými vlastnostmi na H-receptorech, použitelná při léčení alergií a popsaná v patentovém spisu US 4 282 233.
Je známo, že látky, antagonizující účinek leukotrienu je možno použít k léčení asthmatu a také k léčení alergických a zánětlivých stavů.
Vynález si klade za úkol navrhnout nový farmaceutický prostředek pro léčení asthmatu a alergických a zánětlivých stavů, obsahující jako účinnou složku.kombinaci dvou látek s potenciačním účinkem.
Podstata vynálezu
Podstatu vynálezu tvoří farmaceutický prostředek, který jako účinnou složku.obsahuje kombinaci loratadinu a látky, antagonizující leukotrien ze skupiny
A. sodná sůl l-(((R)-(3-(2-(7-chlor-2-chinolinyl)ethenyl)fenyl)-3-(2-(2-hydroxy-2-propyl)fenyl)thio)methyl)cyklopropanacetátu, popsaná v EP 480 717,
- 2 ft ftft • «> '··· ft.·
9 9 9 9 · · · ·» • *· '··»··« «· 9 * ftftft • ft ftft ftft
Sodná sůl montelukastu
B. Sodná sůl l-(((R)-(3-(2-(6,7-difluor-2-chinolinyl)ethenyl)fenyl)-3-(2-(2-hydroxy-2-propyl)fenyl)thio)methyl)cyklopropanacetátu z US 5 270 324,
C. Kyselina l-(((l(R)-(3-(2-(2,3-dichlorthieno/3,2-b/~ pyridin-5-yl)-(E)ethenyl)fenyl)-3-(2-(1-hydroxy-l-methylethyl)fenyl)propyi)thio)methyl)cyklopropanoctová nebo její sodná sůl z US 5 472 964,
D.
N-/4-oxo-2-(lH-tetrazol-5-yl)-4H-l-benzopyran-8-yl/-p-(4-fenylbutoxy)benzamid z EP 173 516,
O
O pranlukast
E.
cyklopentyl-3-/2-methoxy-4-/(o-tolylsulfonyl)karbamoyl/benzyl/-l-methylindol-5-karbamát z EP 199 543
Farmaceutický prostředek podle vynálezu obsahuje kombinaci loratadinu a látky, antagonizující leukotrien ze svrchu uvedených látek A až E a popřípadě obsahuje farmaceuticky přijatelný nosič, vhodný pro enterální nebo parenterální podání. Farmaceutický prostředek může mít pevnou formu, může jít například o tablety a kapsle, nebo kapalnou formu, například sirupy, elixíry, emulze a injekční prostředky. Ve farmaceutických prostředcích tohoto typu se obvykle používají pomocné látky, například voda, želatina, laktosa, škroby, stearan hořečnatý, mastek, rostlinné oleje, benzylalkohol, gumy, póly• · · · • · · · · · • · · · · · • · · · · · · · • · · · ·
- 4 • ·· alkylenglykoly a vazelína. Výhodný prostředek tohoto typu je popsán v následujících příkladech.
Farmaceutický prostředek podle vynálezu je tedy možno použít k léčení svrchu uvedených onemocnění alergické a zánětlivé povahy, zvláště asthmatu.
Požadovaná dávka bude stanovena s ohledem na různé faktory, jako jsou věk, pohlaví, hmotnost a závažnost léčeného onemocnění, přesto je možno uvést, že u člověka bude při perorálním podání výhodná dávka loratadinu 5 až 20 mg 1 až 3x denně, s výhodou přibližně 10 mg jednou denně. V případě leukotrienů je vhodná dávka pro člověka rovněž 5 až 20 mg 1 až 3x denně, s výhodou přibližně 10 mg jednou denně.
Praktické provedení vynálezu bude osvětleno následujícím příkladem složení farmaceutického prostředku.
Příklad provedení vynálezu
Povlékané tablety s obsahem 10 mg sodné soli montelukastu a 10 mg loratadinu
| množství mg | složka | |
| jádro | 10,4 | sodná sůl montelukastu |
| 10,0 | loratadinu | |
| 66,6 | mikrokrystalická celulosa NF | |
| 100,0 | monohydrát laktosy NF | |
| 6,0 | sodná sůl zesítěné karmelosy NF | |
| (60,0) | čištěná voda, USP | |
| 1,0 | stearan hořečnatý, NF | |
| 200,0 | jádro tablety |
/
| • · · · ·· tt · · • · * ···· · · · · • · · · · · · · ··· • · · ··· ··· ··· ·· ··· ·· ·· ·· - 5 - | |
| Povlak filmu | |
| 2,25 | hydroxypropylmethylcelulosa 6 cps |
| 1,25 | hydroxypropylcelulosa, LF |
| 1,50 | oxid titaničitý |
| (33,5) | čištěná voda |
| 205,0 | tablety s povlakem filmu |
Zastupuje :
Claims (12)
- PATENTOVÉ NÁROKY1. Farmaceutický prostředek, vyznačuj ící se t í m , že jako svou účinnou složku obsahuje loratadin a látku, antagonizující leukotrien ze skupinyA) sodná sůl montelukastu,B) sodná sůl l-(((R)-(3-(2-(6,7-difluor-2-chinolinyl)ethenyl)fenyl)-3-(2-(2-hydroxy-2-propyl)fenyl)thio)methylcyklopropanacetátu,C) kyselina l-(((l(R)-(3-(2-(2,3-dichlorthieno/3,2-b/pyridin-5-yl)-(E)-ethenyl)fenyl)-3-(2-(1-hydroxy-l-methylethyl)fenyl)propyl)thio)methyl)cyklopropanoctová nebo její sodná sůl,D) pranolukast aE) zafirlukast, spolu s farmaceuticky přijatelným nosičem.
- 2. Farmaceutický prostředek podle nároku 1, v y značující se tím, že je určen pro perorální podání.
- 3. Farmaceutický prostředek podle nároku 2, v y značující se tím, že obsahuje 10 mg loratadinu a 10 mg látky, antagonizující leukotrien ze skupiny látekA, B, C, D a E.
- 4. Farmaceutický prostředek podle nároku 1, v y značující se tím, že jako látku antagonizující leukotrien obsahuje sodnou sůl montelukastu.• ·· · ·· 9 9 9 99 9 9 9 9 9 9 · · ·9 9 · 9 9 9 · 9 * · ·90 0· 90 99 9999 9099 999 999999 99 999 99 99 09- Ί
- 5. Farmaceutický prostředek podle nároku ^vyznačující se tím, že je určen pro perorální podání.
- 6. Farmaceutický prostředek podle nároku 5, v y značující se tím, že obsahuje 10 mg každé z účinných složek.
- 7. Způsob léčení asthmatu a alergických a zánětlivých stavů, vyznačující se tím, že se podává kombinace loratadinu a účinné látky, antagonizující leukotrien ze skupinyA) sodná sůl montelukastu,B) sodná sůl l-(((R)-(3-(2-(6,7-difluor-2-chinolinyl)ethenyl)fenyl)-3-(2-(2-hydroxy-2-propyl)fenyl)thio)methylcyklopropanacetátu,C) kyselina l-(((l(R)-(3-(2-(2,3-dichlorthieno/3,2-b/pyridin-5-yl)-(E)-ethenyl)fenyl)-3-(2-(1-hydroxy-l-methylethyl)fenyl)propyl)thio)methyl)cyklopropanoctová nebo její sodná sůl,D) pranolukast aE) zafirlukast, v podstatě současně, s výhodou ve formě farmaceutického prostředku podle nároku 1.
- 8. Způsob podle nároku 7,vyznačující se t í m , že se kombinace účinných látek podává ve formě farmaceutického prostředku, určeného pro perorální podání.
- 9. Způsob podle nároku 7,vyznačuj ící se t í m , že se podává
- 10 mg loratadinu a 10 mg látky, antagonizující leukotrien ze skupiny A, B, C, D a E.-βίο. Způsob podle nároku 7,vyznačující se t í m , že se jako látka, antagonizující leukotrien užije sodná sůl montelukastu.
- 11. Způsob podle nároku 10,vyznačuj ící se t í m , že se kombinace podá ve formě farmaceutického prostředku, určeného pro perorální podání.
- 12. Způsob podle nároku 11, vyznačuj íc í se t í m , že farmaceutický prostředek obsahuje 10 mg loratadinu a 10 mg sodné soli montalukastu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1132896P | 1996-02-08 | 1996-02-08 | |
| GBGB9608927.1A GB9608927D0 (en) | 1996-04-29 | 1996-04-29 | Method of treatment and pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ248798A3 true CZ248798A3 (cs) | 1999-01-13 |
Family
ID=26309231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ982487A CZ248798A3 (cs) | 1996-02-08 | 1997-02-04 | Farmaceutický prostředek |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1014972A4 (cs) |
| JP (1) | JPH11504044A (cs) |
| KR (1) | KR19990082367A (cs) |
| CN (1) | CN1210465A (cs) |
| AU (1) | AU732671B2 (cs) |
| BG (1) | BG102669A (cs) |
| BR (1) | BR9707369A (cs) |
| CA (1) | CA2245162A1 (cs) |
| CZ (1) | CZ248798A3 (cs) |
| EE (1) | EE9800234A (cs) |
| IL (1) | IL125446A0 (cs) |
| IS (1) | IS4805A (cs) |
| NO (1) | NO983641L (cs) |
| NZ (1) | NZ331160A (cs) |
| PL (1) | PL328074A1 (cs) |
| SK (1) | SK105698A3 (cs) |
| TR (1) | TR199801511T2 (cs) |
| WO (1) | WO1997028797A1 (cs) |
| YU (1) | YU33298A (cs) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7211582B1 (en) | 1994-12-30 | 2007-05-01 | Sepracor Inc. | Methods for treating urticaria using descarboethoxyloratadine |
| US7214683B1 (en) | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Compositions of descarboethoxyloratadine |
| GB9723985D0 (en) | 1997-11-14 | 1998-01-14 | Zeneca Ltd | Pharmaceutical compositions |
| EP1041990B1 (en) * | 1997-12-23 | 2006-06-28 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| US6194431B1 (en) | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| US6248308B1 (en) | 1998-04-14 | 2001-06-19 | Sepracor Inc. | Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
| AR022378A1 (es) * | 1998-09-10 | 2002-09-04 | Schering Corp | Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas |
| WO2000057880A1 (en) * | 1999-03-29 | 2000-10-05 | Schering Corporation | Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine |
| DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| AU2002227240A1 (en) * | 2000-10-30 | 2002-05-15 | Schering Corporation | Treatment and method using loratadine and montelukast |
| US20020198228A1 (en) * | 2001-04-03 | 2002-12-26 | Kaura Sita R. | Composition and method for the treatment of respiratory desease |
| WO2004087095A2 (es) * | 2003-03-31 | 2004-10-14 | Osmotica Costa Rica, Sociedad Anonima | Dispositivo osmótico que contiene zafirlukast y un antagonista h1 |
| WO2005037245A2 (en) * | 2003-10-21 | 2005-04-28 | Direct-Haler A/S | A multiple route medication for the treatment of rhinitis and asthma |
| WO2005089748A1 (en) * | 2004-03-17 | 2005-09-29 | Pfizer Limited | Combination for treating inflammatory diseases |
| US20060110449A1 (en) | 2004-10-25 | 2006-05-25 | Lorber Richard R | Pharmaceutical composition |
| TR200806298A2 (tr) * | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
| JP2012530140A (ja) | 2009-06-16 | 2012-11-29 | メルク・シャープ・アンド・ドーム・コーポレーション | グルココルチコイド受容体アゴニストとしての新規［３，２−ｃ］ヘテロアリールステロイド、組成物およびこの使用 |
| KR101540191B1 (ko) * | 2014-02-24 | 2015-07-28 | 성균관대학교산학협력단 | 로라타딘을 포함하는 항염증용 조성물 |
| WO2020143744A1 (en) * | 2019-01-10 | 2020-07-16 | Jiangyin Mucocare Pharmaceutical Co., Ltd. | New formulations containing leukotriene receptor antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
| GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| US5270324A (en) * | 1992-04-10 | 1993-12-14 | Merck Frosst Canada, Inc. | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists |
| US5472964A (en) * | 1992-12-22 | 1995-12-05 | Merck Frosst Canada, Inc. | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists |
| US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
-
1997
- 1997-02-04 IL IL12544697A patent/IL125446A0/xx unknown
- 1997-02-04 EE EE9800234A patent/EE9800234A/xx unknown
- 1997-02-04 CA CA002245162A patent/CA2245162A1/en not_active Abandoned
- 1997-02-04 AU AU22579/97A patent/AU732671B2/en not_active Ceased
- 1997-02-04 PL PL97328074A patent/PL328074A1/xx unknown
- 1997-02-04 WO PCT/US1997/001799 patent/WO1997028797A1/en not_active Application Discontinuation
- 1997-02-04 EP EP97905757A patent/EP1014972A4/en not_active Withdrawn
- 1997-02-04 CZ CZ982487A patent/CZ248798A3/cs unknown
- 1997-02-04 KR KR1019980706097A patent/KR19990082367A/ko not_active Application Discontinuation
- 1997-02-04 JP JP9528627A patent/JPH11504044A/ja active Pending
- 1997-02-04 CN CN97192149A patent/CN1210465A/zh active Pending
- 1997-02-04 NZ NZ331160A patent/NZ331160A/xx unknown
- 1997-02-04 SK SK1056-98A patent/SK105698A3/sk unknown
- 1997-02-04 TR TR1998/01511T patent/TR199801511T2/xx unknown
- 1997-02-04 BR BR9707369A patent/BR9707369A/pt not_active Application Discontinuation
-
1998
- 1998-07-22 IS IS4805A patent/IS4805A/is unknown
- 1998-08-05 BG BG102669A patent/BG102669A/bg unknown
- 1998-08-06 YU YU33298A patent/YU33298A/sr unknown
- 1998-08-07 NO NO983641A patent/NO983641L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997028797A1 (en) | 1997-08-14 |
| CN1210465A (zh) | 1999-03-10 |
| SK105698A3 (en) | 1999-05-07 |
| JPH11504044A (ja) | 1999-04-06 |
| NO983641D0 (no) | 1998-08-07 |
| BR9707369A (pt) | 1999-07-20 |
| AU2257997A (en) | 1997-08-28 |
| BG102669A (bg) | 1999-04-30 |
| EE9800234A (et) | 1998-12-15 |
| NZ331160A (en) | 2000-07-28 |
| IL125446A0 (en) | 1999-03-12 |
| YU33298A (en) | 1999-11-22 |
| AU732671B2 (en) | 2001-04-26 |
| PL328074A1 (en) | 1999-01-04 |
| IS4805A (is) | 1998-07-22 |
| KR19990082367A (ko) | 1999-11-25 |
| TR199801511T2 (xx) | 1998-10-21 |
| NO983641L (no) | 1998-08-07 |
| CA2245162A1 (en) | 1997-08-14 |
| EP1014972A4 (en) | 2004-12-08 |
| EP1014972A1 (en) | 2000-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ248798A3 (cs) | Farmaceutický prostředek | |
| AU781177B2 (en) | Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis | |
| KR100296954B1 (ko) | 신규의항알러지항염증조성물 | |
| ES2189232T5 (es) | Microgránulos de omeprazol protegidos gástricamente, procedimiento de obtención y preparaciones farmacéuticas | |
| KR20130006640A (ko) | 라퀴니모드를 이용한 루푸스 신장염의 치료 | |
| US9211264B2 (en) | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea | |
| AU2011268342A1 (en) | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation | |
| CA2328073A1 (en) | Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition | |
| JP2017122115A (ja) | ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト | |
| US20140243351A1 (en) | Drug for the treatment of allergic rhinitis comprising pgd2 antagonist and histamine antagonist | |
| CA2328074A1 (en) | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | |
| CA2337571C (en) | Antihistamine leukotriene combinations | |
| WO2010038240A9 (en) | Pharmaceutical composition comprising nimesulide and levocetirizine | |
| JP2010111667A (ja) | フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物 | |
| KR100523825B1 (ko) | 호흡기감염증 예방제 | |
| EA042135B1 (ru) | Таблетка деферипрона с отсроченным высвобождением и способ ее изготовления | |
| JP2007326824A (ja) | 滑膜細胞増殖抑制剤、並びにこれを利用した薬用組成物及び治療方法 | |
| WO2001003701A1 (en) | An oral composition having as a first active ingredient budesonide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease | |
| JP2010111666A (ja) | セチリジンを含有する鎮咳及び／又は去痰のための医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic |